Biomarkers in Gynaecological Cancer Detection

What Are Biomarkers?

In gynaecology, biomarkers usually mean blood tests that can be associated with certain tumour types or patterns of disease. They may help clinicians to:

• Assess risk when symptoms or scans raise concern

• Guide the next test, such as ultrasound, MRI, hysteroscopy, or biopsy

• Monitor response to treatment in selected diagnoses

• Track recurrence in follow-up for certain tumour types

Biomarkers are best seen as decision-support tools, not standalone answers.

When Biomarker Testing Is Useful

Biomarkers can be considered as part of specialist gynaecological assessment, particularly when there are symptoms, imaging findings, or risk factors that justify further investigation.

Symptoms that should not be ignored

Seek specialist assessment if you have persistent symptoms such as:

• New bloating, abdominal swelling, or early satiety

• Pelvic pain that is ongoing or worsening

• Unexpected bleeding, including after menopause

• Unexplained weight loss, fatigue, or appetite change

• A pelvic mass noted on examination or imaging

Symptoms can have many causes, most of them not cancer. The point is to assess properly and proportionately.

Family history and inherited risk

Biomarkers may be used alongside a structured history when there is:

• A strong family history of ovarian, breast, womb, or bowel cancer

• Known hereditary syndromes in close relatives

• Anxiety driven by risk factors and persistent symptoms

A consultant-led approach matters here because the same test can mean very different things depending on age, menopausal status, and clinical context.

Biomarkers Commonly Used in Gynaecology

Ovarian concerns

The most well-known ovarian biomarker is CA125, but it has important limitations.

• CA125 can be raised for non-cancer reasons, including benign gynaecological conditions.

• CA125 is not recommended as a routine screening test in asymptomatic, average-risk women, because performance is not good enough for that purpose.

In selected situations, consultants may use additional tools such as HE4 and risk algorithms that combine biomarkers with menopausal status, especially when assessing an adnexal mass.

What this means in real life:

• Biomarkers can help risk stratify, not confirm a diagnosis on their own.

• The next step is usually guided by the whole picture, including imaging and examination.

Germ cell tumour markers

In younger women with certain ovarian tumour patterns, consultants may consider markers such as:

• AFP

• beta-hCG

• LDH

These markers are particularly relevant for germ cell tumours, and are often used in diagnosis and monitoring when clinically indicated.

Sex cord stromal tumour markers

For rarer ovarian tumour types such as granulosa cell tumours, clinicians may use:

• Inhibin A or Inhibin B

• AMH

These markers can be useful, especially for follow-up and monitoring in appropriate cases.

Cervix and womb

Many patients assume there is a simple blood test for cervical or womb cancer. In reality:

• There is no single blood biomarker that reliably “screens” for these cancers in the general population.

• Diagnosis usually relies on the right clinical examination and targeted investigations, which may include ultrasound, hysteroscopy, tissue sampling, and specialist imaging when indicated.

Biomarkers Are Not a Diagnosis

This is the key message for anyone searching gynaecological cancer screening London.

A biomarker result can be:

• Normal, even when symptoms still need investigation

• Raised, for reasons that are not cancer

• Borderline, requiring thoughtful interpretation rather than panic

That is why consultant oversight matters. Without context, biomarkers can create unnecessary fear or false reassurance.

How Consultant Assessment Uses Biomarkers Properly

At LSDC Healthcare, biomarker testing is considered as part of a wider, consultant-led pathway that typically includes:

• A detailed symptom and risk review

• Examination when appropriate and with consent

• Pelvic ultrasound and further imaging when clinically indicated

• Biomarkers chosen for a specific question, not as a scattergun panel

• A clear explanation of what results mean and what happens next

The goal is simple: reduce uncertainty, avoid delays, and keep decision-making evidence-informed.

What Your Results Usually Lead To

Depending on your symptoms and findings, results may lead to:

• Reassurance with a follow-up plan, if risk is low and symptoms are settling

• Repeat testing, when trends matter more than a single number

• Targeted imaging such as specialist ultrasound or MRI

• Procedural assessment such as hysteroscopy or tissue sampling, when appropriate

• Referral into a specialist oncology pathway if the clinical picture requires it

No respectable clinic should promise outcomes based on a blood test alone.